Academic Journal

Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin's and Non-Hodgkin Lymphoma

التفاصيل البيبلوغرافية
العنوان: Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin's and Non-Hodgkin Lymphoma
المؤلفون: Gini G., Annibali O., Lupasco D., Bocci C., Tomarchio V., Sampaolo M., Trappolini S., Tafuri M. A., Cacciagiu S., Ciccarone M., Barucca A., Sarlo C., Vincenzi B., Avvisati G., Leoni P., Olivieri A.
المساهمون: Gini, G., Annibali, O., Lupasco, D., Bocci, C., Tomarchio, V., Sampaolo, M., Trappolini, S., Tafuri, M. A., Cacciagiu, S., Ciccarone, M., Barucca, A., Sarlo, C., Vincenzi, B., Avvisati, G., Leoni, P., Olivieri, A.
سنة النشر: 2019
المجموعة: Università Politecnica delle Marche: IRIS
مصطلحات موضوعية: Chemotherapy, Fertility, GnRH analogue, Lymphoma, Administration, Oral, Adolescent, Adult, Amenorrhea, Antineoplastic Combined Chemotherapy Protocol, Contraceptive Agent, Female, Gonadotropin-Releasing Hormone, Hodgkin Disease, Human, Non-Hodgkin, Middle Aged, Recovery of Function, Young Adult
الوصف: Background: Fertility and gonadal function represent one of the most important aspects for long-term lymphoma survivors. Aims: The aim of our study was to determine possible risk factors, such as age at treatment, chemotherapeutic regimen, protection with oral contraceptives (OCs), and gonadotropin-releasing hormone (GnRH) analogues in female patients treated for Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) at a reproductive age. Methods: Patients between the age of 16 and 50 years at the time of HL or NHL diagnosis were selected. Eligible patients were requested to respond to a questionnaire by phone interview about fertility, menstrual status, sexual aspects, and treatment with OCs or GnRH analogues during chemotherapy. Results: The resumption of menstrual activity was associated with the use of the OCs and GnRH analogues during chemotherapy (p = 0.008 and 0.034, respectively). At univariate analysis, the use of OCs during chemotherapy was associated with a lower risk of amenorrhea (prevalence ratio [PR] = 0.37; 95% CI 0.17-0.82). A higher age at the time of treatment correlated positively with therapy-induced amenorrhea, with a difference of 12.8 years between the mean age at diagnosis of the women with therapy-induced amenorrhea and those who resumed their menses. Amenorrhea was significantly higher in women receiving R-CHOP than in women treated with ABVD (PR = 6.00; 95% CI 2.32-15.54). Moreover, NHL had an infertility PR of 1.51 (95% CI 0.86-2.45) at multivariate analysis compared to HL. Conclusions: This study suggests a possible role of pharmacological prophylaxis with OCs and GnRH analogues.
نوع الوثيقة: article in journal/newspaper
اللغة: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/31117081; info:eu-repo/semantics/altIdentifier/wos/WOS:000476513200006; volume:64; issue:1; firstpage:36; lastpage:41; numberofpages:6; journal:CHEMOTHERAPY; http://hdl.handle.net/11566/294582; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85066904906
DOI: 10.1159/000499535
الاتاحة: http://hdl.handle.net/11566/294582
https://doi.org/10.1159/000499535
رقم الانضمام: edsbas.E3057537
قاعدة البيانات: BASE